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Available online xxxxBackground: Lysosomal storage diseases (LSD) often manifest with cherry red macular spots. Diagnosis is based
on clinical features and speciﬁc biochemical and enzymatic patterns. In uncertain cases, genetic testingwith next
generation sequencing can establish a diagnosis, especially in milder or atypical phenotypes. We report on the
diagnostic work-up in a boy with sialidosis type I, presenting initially with marked cherry red macular spots
but non-speciﬁc urinary oligosaccharide patterns and unusually mild excretion of bound sialic acid.
Methods: Biochemical, enzymatic and genetic tests were performed in the patient. The clinical and electrophys-
iological data was reviewed and a genotype-phenotype analysis was performed. In addition a systematic litera-
ture review was carried out.
Case report and results: Cherry redmacular spots were ﬁrst noted at 6 years of age after routine screeningmyopia.
Physical examination, psychometric testing, laboratory investigations aswell as cerebralMRIwere unremarkable
at 9 years of age. So far no clinical myoclonic seizures occurred, but EEG displays generalized epileptic discharges
and visual evoked potentials are prolonged bilaterally. Urine thin layer chromatography showed an oligosaccha-
ride pattern compatible with different LSD including sialidosis, galactosialidosis, GM1 gangliosidosis or
mucopolysaccharidosis type IV B. Urinary bound sialic acid excretion was mildly elevated in spontaneous and
24 h urine samples. In cultured ﬁbroblasts, α-sialidase activity was markedly decreased to b1%; however,
bound and free sialic acid were within normal range. Diagnosis was eventually established by multigene panel
next generation sequencing of genes associated to LSD, identifying two novel, compound heterozygous variants
inNEU1 gene (c.699CNA, p.S233R in exon 4 and c.803ANG; p.Y268C in Exon 5 inNEU1 transcript NM_000434.3),
leading to amino acid changes predicted to impair protein function.
Discussion: Sialidosis should be suspected in patients with cherry red macular spots, even with non-signiﬁcant
urinary sialic acid excretion. Multigene panel next generation sequencing can establish a deﬁnite diagnosis,
allowing for counseling of the patient and family.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Multigene panel next generation sequencing
Lysosomal storage disease
NEU1 gene
Sialidosis
c.699CNA (p.S233R)
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Sialidosis (OMIM #256550) is a rare autosomal recessive lysosomal
storage disorder. It is caused by mutations in the NEU1 gene resulting in
α-sialidase (α-neuraminidase) deﬁciency, leading to insufﬁcient degra-
dation of glycoproteins and subsequent accumulation and excretion ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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described.
Type I: the more common late onset form (second or third decade)
known as ‘cherry-red spotmyoclonus syndrome’withmyoclonus,myo-
clonic epilepsy, visual impairment and ataxia;
Type II: early onset form (infancy/childhood)with progressivemen-
tal retardation, coarse facial features, hepatomegaly, skeletal dysplasia
and severe ataxia [7]. Cherry red macular spots are the hallmark of
both types. Milder or atypical phenotypes, even without cherry red
spot, have been identiﬁed through next generation sequencing in 6 pa-
tients harboring NEU1 variants with inconclusive or nonspeciﬁc bio-
chemical/enzymatic proﬁles. [2]
We report on two novel variants inNEU1 in a boywithmarked cher-
ry red spots but non-speciﬁc urinary oligosaccharide patterns and un-
usually mild urinary excretion of bound sialic acid. Diagnosis was
eventually established through multigene panel next generation se-
quencing of genes associated to lysosomal storage diseases.
2. Materials and methods
2.1. Thin-layer-chromatography of oligosaccharides in urine
Thin-layer-chromatography was performed as previously described
[1,5]. Brief, spontaneous urines were normalized to creatinine and ap-
plied to silicagel 60 plate (10 cm× 20 cm;Merck KGaA, Darmstadt, Ger-
many). Thin-layer-chromatography was performed using a mixture of
n-butanol/acetic acid/H2O (2:1:1 (v/v)). Staining was performed with
orcinol (0.1 g/100 ml) in sulfuric acid/acetone (1:50 (v/v)) at 100 °C.
2.2. Sialic acid in urine and cultivated ﬁbroblasts
Diluted (1:20) spontaneous urines or cultivated skin ﬁbroblasts
(0.5–1.0 mg/ml) were used for the periodate/thiobarbituric assay ac-
cording to the method published by Skoza et al. and Cantz et al. [3,10].
Photometric measurement was performed at an extinction of λ =
549 nm and λ= 532 nm with an inﬁnity M200 pro microplate reader
(Tecan group Ltd., Männedorf, Switzerland).
2.3. Neuraminidase assay
Neuraminidase assay was performed as previously described [4].
After skin biopsy, patient's skin ﬁbroblasts were cultivated. Freshly pre-
pared ﬁbroblast pellets were homogenized under ice water cooling by
using a glass potter. The homogenate was used in the neuraminidase
assay immediately. The assaymixture contained 8 μg BSA, 20–60 μg ho-
mogenate of ﬁbroblasts, 800 pmol 4-methylumbelliferyl-α-D-N-acetyl
neuraminic acid, and 2 μmol sodium acetate buffer (pH 4.3) in a total
volume of 30 μl. After incubation at 37 °C for 30 min the reaction was
stopped by adding 500 μl 0.17 M 0.17 glycine carbonate buffer
(pH 10.0). Fluorescence was measured at an extinction of λ= 360 nm
and an emission of λ= 465 nm with an inﬁnity M200 pro microplate
reader (Tecan group Ltd., Männedorf, Switzerland). Protein concentra-
tion was determined according to the method of Lowry [8].
2.4. Genetic testing
Genetic testing was performed using a targeted panel sequencing
approach to screen for 29 genes known to be involved in lysosomal stor-
age disorders. Analyses were performed similar to the previously de-
scribed method [6]. In brief, coding regions and exon-intron
boundaries were enriched using Agilent SureSelect technology (Agilent
Technologies, Santa Clara, California, USA) followed by next generation
sequencing on an Illumina HiSeq2500 platform (Illumina, San Diego,
California, USA). Reads were aligned using Burrows Wheeler Aligner
(BWA-mem 0.7.2) using hg19 as reference genome. Unambiguous
reads were removed using Picard 1.14. Annotation was performedusing SAMtools (v0.1.18) and VarScan (v2.3). Variants were selected
with a minor allele frequency below 5% (according to 1000 Genomes,
dbSNP, EVS and the CeGaT in-house database). N98% of targets had at
least 30× coverage. Validation of suspicious variants as well as segrega-
tion analysis in both parents were performed by conventional Sanger
sequencing.
2.5. Systematic literature review
A systematic literature review on sialidosis type I with abnormal
metabolic ﬁndings was carried out, using PubMed. Additionally, all re-
ported NEU1 mutations within the Human Gene Mutation Database
(HGMD, https://portal.biobase-international.com/cgi-bin/portal/login.
cgi) that were published until October 2016 were reviewed to identify
cases with atypical metabolic ﬁndings.
3. Case report and results
The patient was referred for further metabolic analysis at the age of
8 years, following the identiﬁcation of cherry red macular spots by his
ophthalmologist two years earlier. Fundus changes were noted, when
he was screened for developing myopia.
He is the ﬁrst child of non-consanguineous German parents. The
family history is unremarkable for genetic disorders, visual impairment
or epilepsy. He has one healthy younger maternal half-sister.
Birth and perinatal periodwere complicated by emergency cesarean
section for intrauterine hypoxia due to placenta infarction and postnatal
aspiration of amniotic ﬂuid. However, mental and motor development
was normal and he shows an age appropriate school performance. Re-
cently, 8 years old, he received screening for attention deﬁcit hyperac-
tivity disorder after the parents noted overactive, twitchy and agitated
behavior. As a consequence, occupational therapy and physiotherapy
were initiated.
Examination revealed a good general condition. Besides atopic der-
matitis, glasses for myopia, and a right convex thoracic scoliosis, inter-
nal, orthopedic, and neurological examination were normal; no facial
dysmorphism, skeletal abnormalities or involuntary movements were
found.
The ophthalmological examination conﬁrmed myopia, and fundos-
copy revealed the cherry redmacula spots (Fig. 1) without signs of atro-
phy of the optic nerve or cataract.
While the patient is still free of clinical seizures, repeated EEG
displayed generalized epileptic discharges. Visual evoked potentials on
both sides showed a mild prolongation of P100 around 130 ms. Brain
magnetic resonance imaging was unremarkable.
On psychometric testing (performed at the age of 9 years using the
German versions of the Wechsler Intelligence Scale for Children
(WISC-IV)), the boy performed normal average (Total Index 108; Verbal
Comprehension Index 115, Perceptual Reasoning Index 108, Working
Memory Index 102, Processing Speed Index 97) without signs of reduced
attention, increased diversion or lack of concentration.
Extensive laboratory investigations revealed unremarkable results
including complete blood count and microscopy (no vacuolated lym-
phocytes), glucose, lactate, ammonia, pH, plasma amino acids, sterol
analysis, dried blood acylcarnitine proﬁle, urinary organic acids,
sulfatides in urine, glycosaminogycanes in urine (by electrophoresis).
In leucocytes, lysosomal enzymes displayed normal activities, excluding
Gaucher's disease andNiemann-Pick disease type A/B are highly unlike-
ly according to normal enzyme analysis. Oxysterols were normal in
plasma, excluding Niemann-Pick disease type C.
Thin layer chromatography of spontaneous urine and a 24-h urine
sample showed an oligosaccharide pattern compatible with sialidosis,
possibly GM1-gangliosidosis, mucopolyaccaridoses IV B (Morquio B),
or galactosialidosis (Fig. 2).
Urine sialic acid (I: spontaneous urine and II: 24-h urine collection)
analysis showed a mildly elevated excretion of bound sialic acid
Fig. 1. Patient's fundoscopy revealed bilateral (A: left; B: right)macular cherry red spot. (For interpretation of the references to colour in thisﬁgure legend, the reader is referred to theweb
version of this article.)
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29.4 mmol/mol crea), while free sialic acid was in the normal range (I:
21.7 mmol/mol crea; II: 22.6 mmol/mol crea, normal range: 12.0–
31.0 mmol/mol crea).
Genomic DNA was extracted from peripheral blood lymphocytes
and panel based next generation sequencing was performed as previ-
ously described [6]. Two different missense variants (c.699CNA,
p.S233R in exon 4 and c.803ANG; p.Y268C in Exon 5 in NEU1 transcript
NM_000434.3) were identiﬁed present in compound heterozygous
state conﬁrmed by Sanger sequencing.
Further segregational studies showed that the p.S233R variant was
ofmaternal origin. Analysis of the Father was not possible. Both variants
are absent frommutation databases, such as Human GeneMutation Da-
tabase and ClinVar. In the 60,706 controls of the ExacBrowser, the allele
c.699A is found once in a heterozygous state in a control of African ori-
gin while c.803G is absent; no homozygous carriers are present in the
database (http://exac.broadinstitute.org/). The variant p.S233R leads
to an amino acid change from the highly conserved serine to arginine
at position 233 and p.Y268C leads to a change from the conservedFig. 2.Oligosaccharide thin layer chromatographywith orcinol in spontaneous urine. Lane
a: normal control Lane b: dextran hydrolysate Lane c: urine specimen of the patient Lane
d: standardmixture of glucose, saccharose and lactose. The bandsmarkedwith arrows are
the bands leading to the suspected diagnosis of sialidosis or GM1-gangliosidosis,
mucopolysaccharidosis IV B (Morquio B), or galactosialidosis.residue tyrosine to cysteine at position 268. Both variants are predicted
to damage protein functionwith high scores in standard in silico predic-
tion tools (PolyPhen2, http://genetics.bwh.harvard.edu/pph2, and
MutationTaster, http://www.mutationtaster.org) using the NEU1 tran-
script NM_000434.3.
α-neuraminidase activity, measured in the patient's cultured ﬁbro-
blasts, showed a markedly decreased enzyme activity to b1% of the
norm. However, both bound and free sialic acid in the cultured ﬁbro-
blasts were within the normal range. Additionally GM1-Gangliosidosis,
mucopolysaccharidosis Type IV B and β-Galactosidase were excluded
by determination of enzyme activity in cultured ﬁbroblasts.
At last follow-up, the boy was ten years 4 month old with a good
school performance (secondary school). No overt epileptic seizures
have been reported although EEG displays epileptic discharges at in-
creasing frequency/severity compatible with developing myoclonic
epilepsy.
The systematic literature review on patients with sialidosis and ab-
normal mild metabolic ﬁndings was performed in PubMed and with
the Human Gene Mutation Database. A total of 9 previously described
patients with sialidosis type I or biallelic NEU1 variants that resulted in
a mild biochemical phenotype were identiﬁed. Characteristics of these
patients are condensed in Table 1. Interestingly, like our index patient,
all reported patients displayed not or only mildly elevated bound sialic
acid excretion in urine in combination with a pronounced decrease in
α-neuraminidase activity. However, our index patient is exeptional
among this group, as he is by far the youngest individual and his clinical
phenotype is in contrast to the group not atypical but compatible with
typical sialidosis type I.
4. Discussion
The ﬁnding of cherry redmacular spots is indicative for several lyso-
somal storage disorders. It is caused by the storage of oligosaccharides
and sphingolipids in the retinal ganglionic cell layer.
Urinary oligosaccharides, urinary bound sialic acid excretion, and
enzyme assay in leukocytes and cultured ﬁbroblasts can establish the
diagnosis of sialidosis. However, interpretation of pathological thin
layer chromatography of urine oligosaccharides might be difﬁcult and
not speciﬁc and increased urinary sialic acid excretion is not a constant
ﬁnding in patients with sialidosis I [11]. This corresponds to the still
expanding clinical spectrum of sialidosis to milder or atypical pheno-
types [2,9].
In contrast to the patients reported by Canafoglia and colleagues [2],
our patient displayed cherry red macular spots and EEG changes com-
patible with developing myoclonic epilepsy which might be further
suspected from the parents reports of hyperactivity and irritability. To
our knowledge, we report on the youngest patient, being younger
Table 1
Characteristics of reported patients with Sialidosis type I with normal/mild metabolic ﬁndings
Patient, sex #1 #2, M #3, F #4, F #5, F #6, F #7, M #8, F #9, F Index patient
Reference [11] [2]
[9] This report
Mutation, protein n.a. c.200CNT,p.S67I
(homozygous)
c.679GNA, p.G227R; c.913CN
T,p.R305C
c.1195_1200dup,
p.His3999_Tyr400dup;
c.679GNA, p.Glu277Arg
c.699CNA, p.S233R; c.803ANG, p.Y268C
Age at onset [y] n.a. 23 25 22 25 25 32 12 13 6
Cherry red spot n.a. None None None None None None Yes Yes Yes
Seizures/myoclonus n.a. None None None None None None Yes Yes EEG: epileptic discharges
Ataxia n.a. None Yes Yes None None None Yes Yes None
Age at diagnosis [y] 48 27 34 30 42 37 36 13 14 8
Bound sialic acida normal 59 90 114 41 50 59 57 38 50.7
α-Neuraminidaseb [%] ↓ 0 0 0 1 15 3 1,1 1,1 b1
n.a. – not available
a Normal values: b57–60 mmol/mol creatinine.
b % of normal values/activity of the normal control.
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oping clinical and electrophysiological signs of sialidosis.
Thus, sialidosis might be suspected in patients with cherry red mac-
ular spots even if urinary excretion of bound sialic acid is onlymildly el-
evated and oligosaccharide pattern are suspicious. Our report further
supports the aid of multigene panel sequencing to differentiate lyso-
somal storage diseases and to identify novel mutations. Enzymatic as-
says in patient's ﬁbroblasts showed a severely impaired enzyme
function and provides further evidence for the pathogenicity of both
NEU1 variants leading to compound heterozygosity of disease in our
patient.
5. Conclusion
Sialidosis, and by interference other lysosomal storage disorders,
should not be eliminated from the list of differential diagnosis in pa-
tients with cherry red macular spots based on normal urinary sialic ex-
cretion alone. If the level of clinical suspicion is high, even themultigene
panel next generation sequencing is justiﬁed to support a deﬁnite diag-
nosis, in turn allowing for informed patient advice.
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